As more data begins to emerge from clinical trials investigating tau-targeted therapies in AD patients (Congdon and Sigurdsson, 2018; Ayalon et al., 2021), a QSP model platform could be developed for tau pathology in AD or an existing model could be expanded. This evidence concerns the gene MAPT and Alzheimer disease.